Valle, J., Abou-Alfa, G., Kelley, R., Lowery, M., Shroff, R., Bian, Y., . . . Javle, M. Quantitative benefit–risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with mIDH1 cholangiocarcinoma. Elsevier.
Chicago Style (17th ed.) CitationValle, J.W, et al. Quantitative Benefit–risk Assessment of Data from the Phase III ClarIDHy Study of Ivosidenib Versus Placebo in Patients with MIDH1 Cholangiocarcinoma. Elsevier.
MLA (9th ed.) CitationValle, J.W, et al. Quantitative Benefit–risk Assessment of Data from the Phase III ClarIDHy Study of Ivosidenib Versus Placebo in Patients with MIDH1 Cholangiocarcinoma. Elsevier.
Warning: These citations may not always be 100% accurate.